Multiple Sclerosis Therapeutics Market is expected to reach US$ 39,223.59 Mn by 2027

Immunomodulators Segment to Grow at Highest CAGR During 2020–2027

According to our new market research study on “Multiple Sclerosis Therapeutics Market to Forecast 2027 – COVID-19 Impact and Global Analysis – by Drug Class, Route of Administration, and Distribution Channel,” the market is expected to reach US$ 39,223.59 million by 2027 from US$ 24,026.90 million in 2019. The market is estimated to grow at a CAGR of 6.5% from 2020 to 2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth.  

Based on drug class, the market is segmented into immunosuppressant and immunomodulators. In 2019, the immunomodulators segment accounted for larger share of the market. Growth of this segment is attributed to launch of new generic drugs and increase in adoption of immunomodulators in multiple sclerosis (MS) treatment. The immunosuppressant segment is likely to register higher CAGR during the forecast period.

Based on route of administration, the multiple sclerosis therapeutics market is segmented into injectable and oral. The injectable segment held larger share of the market in 2019, and same segment is anticipated to register higher CAGR during the forecast period.

Based on distribution channel, the multiple sclerosis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held the largest share of the market in 2019, and the e-commerce segment is anticipated to register the highest CAGR in the market during the forecast period.

COVID-19 pandemic has become the most significant challenge across the world. This would be difficult, especially for developing countries across the globe, as it may lead to reduction in imports due to disruptions in global trade. Till date, no definitive treatment against COVID-19 has been established. Patients with severe health conditions, such as neurological diseases, are witnessing delays in treatment. Supply chain disruptions associated with this pandemic situation would ultimately affect the sales of products for a short period. However, the supply of MS drugs has been continuous in the pandemic as pharmacies are allowed to stay open during the lockdown. Several companies are cutting their clinical trial activities and delaying product launches in response to the COVID-19 pandemic. For instance, Bristol-Myers Squibb delayed the launch of its multiple-sclerosis drug Zeposia (ozanimod) due to the COVID-19 pandemic.

Merck & Co., Inc.; Novartis AG; Bayer AG; Sanofi; Bristol-Myers Squibb Company; Horizon Therapeutics plc.; Teva Pharmaceutical Industries Ltd; Takeda Pharmaceutical Company Limited; F. Hoffmann-La Roche Ltd., and Biogen are among the leading companies operating in the multiple sclerosis therapeutics market.

Multiple Sclerosis Therapeutics Market, by Region, 2019 (%)

---

Multiple Sclerosis Therapeutics Market to Grow at a CAGR of 6.5% to reach US$ 39,223.59 Million from 2020 to 2027

Download Free Sample

---

Multiple Sclerosis Therapeutics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class (Immunosuppressant and Immunomodulators), Route of Administration (Injectable and Oral), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce), and Geography

The report segments global multiple sclerosis therapeutics market as follows:

By Drug Class

• Immunosuppressant
• Immunomodulators

By Route of Administration     

• Injectable
• Oral

By Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

By Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe
• Asia Pacific (APAC)
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East & Africa
• South America (SAM)
  • Brazil
  • Argentina
  • Rest of South America

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com